HRT Cuts Dementia Risk for Women
A study of over 180,000 postmenopausal women in the UK found that hormone replacement therapy (HRT) lowered dementia risk by 10% overall and 16% for Alzheimer’s. The research, led by Prof Anne-Marie Minihane of the Norwich Institute for Healthy Ageing, followed participants for an average of 13 years using UK Biobank data.
Study Overview
A large observational study tracked 183,450 postmenopausal women in the United Kingdom for an average of 13 years, using data from the UK Biobank. The researchers, headed by Prof Anne-Marie Minihane of the Norwich Institute for Healthy Ageing at the University of East Anglia, examined whether using any form of hormone replacement therapy (HRT) for at least one year was associated with a lower risk of developing dementia. The analysis identified almost 4,000 cases of dementia during the follow-up period.
The study was published in the journal Alzheimer’s & Dementia and is the largest of its kind to date. It relied on observational data, meaning that while associations were found, a causal relationship cannot be definitively established.
Risk Reductions by Group
The researchers reported several percentage reductions in dementia risk linked to HRT use. The most striking findings are summarised in the table below:
| Group | Any dementia | Alzheimer’s |
|---|---|---|
| All HRT users | 10% lower risk | 16% lower risk |
| Surgical menopause | 26% lower risk | - |
| Low lifetime estrogen exposure | 16% lower risk | - |
Women who had undergone surgical menopause experienced the greatest overall reduction, with a 26% lower risk of any type of dementia compared with non-users. Those who naturally had lower estrogen exposure during their lifetime-either from late or early onset of menstruation-also benefited, showing a 16% lower risk of any dementia.
Genetic and Hormonal Factors
The study highlighted that the protective association of HRT was stronger in women carrying the Apoe4 gene variant, which is known to increase Alzheimer’s risk. Prof Minihane noted that “Apoe4 carriers are typically considered at higher risk and have fewer established prevention options.” The data suggest that HRT may offer a particular benefit for this genetically vulnerable group.
The researchers also considered socioeconomic factors, noting that HRT users had a higher average level of education than non-users. While adjustments were made for such variables, the authors acknowledged that residual confounding could still influence the observed associations.
Limitations and Expert Opinion
Because the study is observational, it cannot prove that HRT causes the reduction in dementia risk. Dr Susan Kohlhaas, executive director of research and partnerships at Alzheimer’s Research UK, emphasised that the findings “are not enough to tell us whether HRT should be used to reduce dementia risk, but they provide further evidence that the timing of HRT and a woman’s hormonal history may matter.” She called for research that can establish causality and determine which forms of HRT might be most effective.
The study also pointed out that HRT users had higher education levels, a factor that could independently lower dementia risk. Even after statistical adjustments, the possibility remains that other differences between users and non-users could explain part of the association.
Practical Take-away
Women who are considering starting or stopping HRT should discuss the potential benefits and risks with their general practitioner. The study suggests that for some postmenopausal women-particularly those with surgical menopause or carrying the Apoe4 allele-HRT may offer a modest reduction in dementia risk, but individual circumstances and medical history must guide decision-making.
The research draws on stats from the UK Biobank and references the long-term follow-up recorded in the fixtures database.
